NOVO-111 / InnovoTEX - LARVOL DELTA

NOVO-111: A macrocycle drug conjugate engineered for improved tumor targeting and tolerability (AACR 2026) - "Background: NOVO-111 is a novel gadolinium(III) texaphyrin-platinum(IV) complex designed as a tumor-affinic prodrug of oxaliplatin (1,2-diaminocyclohexane-platinum(II) oxalate). NOVO-111 displays unique PK and tumor-targeting characteristics that yield improved therapeutic performance relative to oxaliplatin. Prolonged Pt(II) persistence, enhanced tumor accumulation, and favorable tolerability together support its advancement as a next-generation platinum-based therapeutic for colorectal and other solid tumors. These findings underscore the translational potential of texaphyrin-guided delivery platforms to overcome long-standing limitations of traditional platinum chemotherapy."

Oncology • Ovarian Cancer • Solid Tumor • Testicular Cancer • KRAS

Profiling the Preclinical Pharmacokinetics and Biodistribution of a Platinum(IV)-Based Oxaliplatin Prodrug OxaliTEX and Their Significance to Antitumor Response. (PubMed, Mol Pharm) - "OxaliTEX (NOVO-111) is a novel gadolinium(III) texaphyrin-platinum(IV) complex that is under development for clinical trials. This suggests that other factors, such as the slow plasma terminal phase of the free Pt(II) species from oxaliTEX that prolongs exposure to low drug concentrations, may contribute to the favorable in vivo antitumor activity and therapeutic index of the conjugate. These characteristics demonstrate superiority of oxaliTEX and generate much optimism for its success in future clinical trials."

Journal • PK/PD data • Preclinical • Oncology • KRAS

Macrocycle drug conjugate NOVO-111 induces ribosome biogenesis stress and is efficacious in colorectal cancer xenografts (AACR 2025) - "Results indicate that NOVO-111 is capable of inducing RBS as a potential anticancer mechanism in human CRC cells. In addition, NOVO-111 was found to induce a statistically significant tumor growth delay and increase survival in CRC PDX models compared to oxaliplatin. These data demonstrate that NOVO-111, as an MDC, has a distinct advantage over the current standard of care for CRC."

Colorectal Cancer • Oncology • Solid Tumor